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Methicillin-resistant  Staphylococcus aureus (MRSA) 
infections and methamphetamine use are emerging public 
health problems. We conducted a case–control investiga-
tion to determine risk factors for MRSA skin and soft tissue 
infections (SSTIs) in residents of a largely rural southeast-
ern community in the United States. Case-patients were 
persons >12 years old who had culturable SSTIs; controls 
had no SSTIs. Of 119 SSTIs identiﬁ  ed, 81 (68.1%) were 
caused by MRSA. Methamphetamine use was reported in 
9.9% of case-patients and 1.8% of controls. After we ad-
justed for age, sex, and race, patients with MRSA SSTIs 
were more likely than controls to have recently used meth-
amphetamine (odds ratio 5.10, 95% conﬁ  dence  interval 
1.55–16.79). MRSA caused most SSTIs in this population. 
Transmission of MRSA may be occurring among metham-
phetamine users in this community. 
M
ethicillin-resistant Staphylococcus aureus (MRSA) 
is a growing public health problem for urban and ru-
ral communities in the United States (1,2). Skin and soft 
tissue are the most common sites of MRSA infection, com-
prising >75% of MRSA disease (3,4). Skin and soft tissue 
infections (SSTIs), commonly caused by S. aureus, annu-
ally account for an estimated 11.6 million visits to hospital 
outpatient departments and emergency departments in the 
United States (5), and the percentage of SSTIs caused by 
MRSA in urban emergency departments increased from 
29% in 2001 and 2002 to 64% in 2003 and 2004 (6). Some 
of the ﬁ  rst reports of MRSA were in injection drug users in 
urban Detroit during the early 1980s (7,8).
Illegal methamphetamine use in the United States led 
to a rising number of methamphetamine-related hospital 
admissions from the early 1980s through the early 2000s 
(9). In 2004, 0.2% of the national population >12 years 
of age reported using methamphetamine in the previous 
month; 0.6% reported using it in the previous year (10). 
The prevalence of methamphetamine use has been reported 
to be >5% in at-risk populations such as young men from 
low-income, urban neighborhoods (11) and urban HIV-
positive men who have sex with men (12).
On August 2, 2005, the Georgia Division of Public 
Health invited the Centers for Disease Control and Preven-
tion (CDC) to assist in an on-site investigation of increased 
SSTIs among patients of a low-cost, fee-for-service clinic 
in rural Georgia. The clinic’s nurse practitioner had noted a 
history of methamphetamine use in multiple patients with 
SSTIs. Methamphetamine use has been associated with 
MRSA skin infections among urban HIV-positive men who 
have sex with men (12), but no study has evaluated the as-
sociation of methamphetamine use and MRSA infection in 
a community with a large rural population. The objectives 
of this investigation were to deﬁ  ne the public health effects 
and to determine risk factors, including methamphetamine 
use, for MRSA SSTI among residents of a community in 
the southeastern United States.
Methods
Epidemiologic Investigation
We conducted a prospectively enrolled case–control 
investigation at 3 emergency departments and 3 urgent care 
clinics in Georgia from September 6 through October 31, 
2005. Two low-cost urgent care clinics that serve primarily 
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low-income populations and all emergency departments in 
a 3-county area were included in an attempt to capture sites 
where methamphetamine users might seek medical care for 
SSTI. The third urgent care clinic was afﬁ  liated with one of 
the participating hospitals but was located in a neighboring 
county. According to the 2000 US Census, 43.9% of the 
population of these 3 counties lives in rural areas (13).
We deﬁ  ned a case-patient as a person >12 years of age 
with a laboratory culture–conﬁ  rmed SSTI who came to a 
participating emergency department or clinic for treatment 
during the investigation period. Clinicians at participating 
institutions identiﬁ  ed patients with culturable SSTIs and 
were asked to incise, drain, and culture all infected skin 
and soft tissue. Patients with SSTIs that were not cultur-
able, such as simple cellulitis, were not included. Patients 
whose primary language was not English were enrolled if 
they could speak English ﬂ  uently enough to answer survey 
questions. Patients with new or recurrent SSTI could also 
be enrolled; however, we excluded patients who had previ-
ously enrolled in the investigation.
Controls were patients >12 years of age with no current 
skin infection who were frequency matched by investiga-
tion site at a rate of 3 controls to 1 case-patient with MRSA 
infection. Controls were excluded if they reported a current 
skin infection or if infection was identiﬁ  ed on physical ex-
amination. Persons could be enrolled as control patients if 
illness was minor and comparable in severity to an SSTI. 
For example, patients with major trauma and critically ill 
patients were excluded from control selection.
Upon seeking treatment, patients voluntarily consent-
ed to be interviewed by trained staff of the participating 
healthcare facilities, local public health departments, or 
CDC to identify SSTI case-patients. To ensure as much 
privacy as possible, the interviews were usually conducted 
in the patient’s room with no family or friends present. The 
interview survey contained questions about demographics, 
clinical history, and potential risk factors for SSTI. Each 
patient was asked a speciﬁ  c question about methamphet-
amine use: “In the past 3 months, have you used metham-
phetamine (crystal meth or meth)?” If the patient answered 
yes, 2 follow-up questions were asked: 1) “How did you 
take methamphetamine?” with the choices “smoked or 
inhaled,” “injected,” or “swallowed or took pills,” and 2) 
“Have you shared drug equipment or rinse water with any-
one else, including a signiﬁ  cant other?” To identify health-
care exposure, patients were asked whether they had had 
surgery or dialysis or if they had stayed overnight in a hos-
pital within the previous 3 months. All patients, and their 
parents if the patients were <18 years of age, were given a 
letter explaining the investigation and asked to give verbal 
informed consent to enroll in the investigation. 
We examined trends in S. aureus skin infections and 
cultures at one of the main emergency departments in our 
investigation by reviewing billing codes and laboratory mi-
crobiology reports from January 2004 through September 
2005, the start of the case–control survey investigation. 
This investigation was deemed exempt from review by the 
CDC Institutional Review Board because it was part of a 
public health response by CDC and the Georgia Division 
of Public Health.
Laboratory Investigation
Specimens were obtained from at least 1 infection 
site in all case-patients. Staff at all 3 hospital emergency 
departments and the urgent care clinic afﬁ  liated with 1 
of the hospitals collected cultures and performed antimi-
crobial drug susceptibility testing at their facility. Two 
low-cost, urgent care clinics sent all cultures to CDC for 
culture and antimicrobial drug susceptibility testing. All 6 
investigation sites sent both MRSA and methicillin-sus-
ceptible S. aureus (MSSA) isolates to CDC for further 
characterization.
All available isolates from methamphetamine users and 
a random sample of isolates not related to methamphetamine 
use from each of the 6 investigation sites were tested at CDC 
for antimicrobial susceptibility by the Clinical and Labora-
tory Standards Institute broth microdilution method (14). We 
tested for susceptibility to chloramphenicol, clindamycin, 
daptomycin, doxycycline, erythromycin, gentamicin, levo-
ﬂ   oxacin, linezolid, oxacillin, penicillin, rifampin, tetracy-
cline, trimethoprim-sulfamethoxazole, and vancomycin. In 
addition, we performed the cefoxitin disk diffusion test to 
predict mecA-mediated resistance to oxacillin (14) and the 
D-zone test for inducible clindamycin resistance (15). Iso-
lates were also tested by using PCR for genes encoding the 
staphylococcal cassette chromosome mec (SCCmec) resis-
tance complex, Panton-Valentine leukocidin (PVL) cytotox-
in, and toxic shock syndrome toxin (16). Chromosomal DNA 
was analyzed by pulsed-ﬁ  eld gel electrophoresis (PFGE) af-
ter digestion with SmaI restriction endonuclease (17). The 
relatedness of PFGE patterns in different isolates was deﬁ  ned 
by using Dice coefﬁ  cients and 80% relatedness by the un-
weighted pair-group method with arithmetic averages (Ap-
plied Maths, BioNumerics, Austin, TX, USA) (18).
Statistical Methods
We conducted univariate analysis of the data to de-
scribe patient demographics and compared binary and 
categorical variables with the χ2 test; continuous variables 
were compared by using the t test with unequal variances. 
We evaluated risk factors for MRSA SSTIs by using condi-
tional logistic regression with stratiﬁ  cation by investigation 
site. Risk estimates were adjusted for age (categorized as 
<18 years, 19–34 years, 35–64 years, and >65 years), sex, 
and race (categorized as white and nonwhite) because they 
were potential confounding variables.
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Results
Epidemiologic Investigation
We identiﬁ   ed 119 case-patients with skin infec-
tions in the investigation. MRSA was isolated from 81 
(68.1%) of the skin and soft tissue cultures, MSSA from 20 
(16.8%), and bacteria other than S. aureus from 18 (15.1%) 
(Table 1). Compared with controls with no skin infection, 
a higher percentage of patients with MRSA SSTIs were 
male (p<0.001). The proportion of patients that were male 
did not differ signiﬁ  cantly between controls and patients 
with either MSSA or non–S. aureus SSTIs (p = 0.67 for 
MSSA, p = 0.12 for non–S. aureus) or between patients 
with MRSA and MSSA SSTIs (p = 0.16).
Fifteen patients who reported recently using metham-
phetamine were identiﬁ  ed: 8 with MRSA SSTIs, 2 with 
MSSA SSTIs, and 5 controls. Half (8 [53.3%]) of the meth-
amphetamine users were male. Ten percent of patients with 
MRSA skin infections (8/81) reported using methamphet-
amine in the past 3 months, signiﬁ  cantly more than the 2% 
of controls (5/283) who reported this behavior (p<0.001). 
After adjusting for age, sex, and race, we determined that 
patients with MRSA SSTI were signiﬁ  cantly more likely 
to have recently used methamphetamine than were con-
trols (adjusted odds ratio [AOR] 5.10, 95% conﬁ  dence 
interval [CI] 1.55–16.79) (Table 2). Of the 8 methamphet-
amine users with MRSA SSTIs, most (5 [62.5%]) smoked 
or inhaled the drug. Only 1 (12.5%) injected the drug, and 
1 (12.5%) took the drug orally. For 1 methamphetamine 
user with MRSA SSTI, we could not determine the route 
of drug administration. Of the 8 methamphetamine users 
with MRSA SSTIs in our investigation, 2 (25.0%) reported 
sharing drug equipment or rinse water with other persons; 
we did not have information on drug-sharing behavior for 1 
methamphetamine user with a MRSA SSTI. 
In our study population, having had a skin infection 
within the previous 3 months was the factor most strongly 
associated with current MRSA skin infection (AOR 7.92, 
95% CI 4.10–15.28) (Table 2). Recent sexual contact with 
someone with a skin infection was also a signiﬁ  cant risk 
factor for MRSA skin disease (AOR 5.42, 95% CI 1.68–
17.50), when compared with recent sexual contact with 
a person without a skin infection. Frequent skin-picking 
behavior was independently associated with MRSA SSTI 
(AOR 2.53, 95% CI 1.22–5.23). Crowded living condi-
tions, deﬁ  ned as >1 person per bedroom, had a small but 
signiﬁ  cant association with MRSA SSTI (AOR 1.78, 95% 
CI 1.004–3.15).
Only 10% of MRSA case-patients had healthcare-asso-
ciated risk factors traditionally associated with MRSA in-
fection, namely, recent hospitalization, surgery, or dialysis. 
Additional factors not signiﬁ  cantly associated with MRSA 
SSTI in our study population included use of antimicrobial 
agents in the previous 6 months, recent stays in a jail or 
prison, bathing less than daily, history of diabetes or liver 
disease, recent tattoo or body piercing, and participation in 
contact sports in the previous 3 months. In addition, very 
few or no patients were HIV positive (2 [0.5%]), homeless 
(0), or recently had sex with someone of the same sex (7 
[1.6%]), suggesting that none of these were signiﬁ  cant risk 
factors for MRSA SSTI in this population.
The number of visits for S. aureus skin infections at 
one of the main emergency departments in our investiga-
tion increased from ≈1 per 1,000 emergency department 
visits to 12 per 1,000 visits over the 20 months leading up 
to the investigation (Figure 1). This emergency department 
accounted for 46.2% of all study participants in our inves-
tigation. Over the same period, MRSA infections increased 
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Table 1. Demographic characteristics of study participants with (case-patients) and without (controls) skin and soft tissue infections
(SSTIs)*
Patients with SSTIs 
Characteristic MRSA (N = 81), no. (%)  MSSA (N = 20), no. (%)  Other† (N = 18), no. (%) 
Patients without SSTIs 
(N = 284), no. (%) 
Age, y 
<18 12 (14.8)  0 2 (11.1)  18 (6.3) 
   19–34  30 (37.0)  13 (65.0)  8 (44.4)  102 (35.9) 
   35–64  35 (43.2)  6 (30.0)  7 (38.9)  135 (47.5) 
>65 4 (4.9)  1 (5.0)  1 (5.6)  29 (10.2) 
Male sex‡  48 (59.3)§  8 (40.0)  10 (55.6)  104 (36.6) 
Race¶
   White  73 (90.1)  18 (90.0)  16 (88.9)  244 (85.9) 
   Black  5 (6.2)  2 (10.0)  2 (11.1)  36 (12.7) 
   Other  3 (3.7)  0 0 3 (1.1) 
Hispanic ethnicity#  2 (2.5)  0 0 4 (1.4) 
*MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S. aureus.
†Bacteria other than S. aureus isolated from SSTI in our investigation included other Staphylococcus spp., viridans group streptococci, Group B 
Streptococcus, Enterobacter cloacae, Stenotrophomonas maltophilia, and mixed flora. 
‡6 records did not indicate sex (1 MRSA case, 1 MSSA case, and 4 controls). 
§p<0.0001, when compared with controls. 
¶For 1 control, race was not indicated. 
#3 records did not indicate ethnicity (2 MRSA cases, 1 other skin infection). RESEARCH
from 2 to 38 per month in the same emergency department. 
Most emergency department S. aureus cultures for both 
SSTIs and non-SSTIs were resistant to methicillin, with the 
prevalence of methicillin-resistance remaining stable over 
the same 20-month period (median 82%, range 50–100%).
Laboratory Investigation
MRSA (n = 32) and MSSA (n = 13) isolates tested 
were commonly susceptible to clindamycin, daptomycin, 
doxycycline, gentamicin, levoﬂ  oxacin, linezolid, rifampin, 
tetracycline, trimethoprim-sulfamethoxazole, and vanco-
mycin (Table 3). None of the MRSA isolates and only 1 
(7.7%) of the MSSA isolates had inducible clindamycin 
resistance. MRSA susceptibility patterns of isolates from 
methamphetamine users and nonusers were similar, except 
that both MRSA isolates susceptible to erythromycin were 
found in those who did not use methamphetamine. The 
MSSA isolate from a methamphetamine user was suscep-
tible to all but penicillin.
We detected genes for PVL in all MRSA isolates and 
5 (41.7%) MSSA isolates; however, the MSSA isolate 
from a methamphetamine user did not carry the PVL locus. 
All available MRSA isolates from 6 methamphetamine 
users and 21 nonusers of methamphetamine had type IV 
SCCmec resistance complex and were PFGE type USA300. 
Most of the MRSA isolates were a single strain, PFGE type 
USA300-0114 (4 [66.7%] were methamphetamine users, 
15 [71.4%] were non-methamphetamine users) (Figure 2). 
One third (33.3%) of MRSA isolates from methamphet-
amine users and one ﬁ  fth (19.0%) of MRSA isolates from 
non-methamphetamine users were variants of USA300-
0114, such as USA300-0047.
Discussion
MRSA caused over two thirds of all skin infections in 
the Georgia community we investigated, which is among 
the highest reported rates of MRSA in SSTI nationwide 
(16). We found that many previously known risk factors 
for MRSA skin infection, such as recent skin infection and 
household contact with someone with a skin infection (19), 
were common in this population. However, we also identi-
ﬁ  ed a novel association between MRSA skin infections and 
methamphetamine use in a community with a large rural 
population. Methamphetamine use was reported in nearly 
1 in 10 patients with MRSA SSTI and was more common 
in patients with MRSA skin infections than in patients 
without skin infections. While most community-associated 
MRSA SSTI occur in persons without deﬁ  ned risk factors 
(16), some settings such as prisons and military training 
facilities appear to facilitate and amplify MRSA transmis-
sion (20,21). A similar ampliﬁ  cation of transmission may 
be occurring among methamphetamine users in this com-
munity.
Methamphetamine use is associated with a number of 
socioeconomic and behavioral risk factors that may pre-
dispose persons to MRSA SSTI. We found that MRSA 
SSTI was associated with living with someone with a skin 
infection, which may increase skin contact with infected 
persons. Skin-picking was also associated with MRSA 
SSTI. Methamphetamine use causes formication, a sensa-
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no. (%)  Crude OR (95% CI)  Adjusted OR† (95% CI)
Drug use and medical history 
  Recent skin infection‡  34 (42.0)  22 (7.8)  8.41 (4.54–15.59)  7.92 (4.10–15.28) 
  Recent methamphetamine use‡  8 (9.9)  5 (1.8)  5.64 (1.80–17.69)  5.10 (1.55–16.79) 
  Antimicrobial agents within 6 months  40 (49.4)  114 (40.1)  1.43 (0.87–2.34)  1.52 (0.89–2.60) 
  Recent hospitalization, surgery, or dialysis‡  8 (9.9)  27 (9.5)  1.06 (0.46–2.44)  1.24 (0.51–2.97) 
  Diabetes  10 (12.4)  23 (8.1)  1.61 (0.73–3.57)  2.03 (0.83–4.98) 
  Liver disease  1 (1.2)  9 (3.2)  0.38 (0.05–3.07)  0.59 (0.70–4.91) 
Contact exposure 
  Household contact with someone with skin  
 infection 
21 (25.9)  27 (9.5)  3.26 (1.72–6.17)   3.19 (1.58–6.48) 
  Crowding (>1 person/bedroom)  44 (54.3)  111 (39.1)  2.06 (1.22–3.45)   1.78 (1.004–3.15)§ 
  Recent sexual contact‡  48 (59.3)  182 (64.1)  0.85 (0.51–1.42)   0.68 (0.38–1.22)  
  Recent sexual contact with someone with  
 skin  infection‡ 
7 (8.6)  6 (2.1)  4.28 (1.40–13.08)   5.42 (1.68–17.50)  
  Recent contact sports‡  9 (11.1)  11 (3.9)  2.92 (1.17–7.31)   1.37 (0.47–4.03)  
  Recent jail‡  4 (4.9)  9 (3.2)  1.46 (0.44–4.90)  1.75 (0.48–6.42)  
Hygiene practices 
  Frequent skin picking  17 (20.1)  24 (8.5)  2.77 (1.40–5.47)   2.53 (1.22–5.23)  
  Bathe less than daily  5 (6.2)  31 (10.9)  0.50 (0.19–1.34)  0.56 (0.19–1.67)  
*MRSA, methicillin-resistant Staphylococcus aureus; OR, odds ratio; CI, confidence interval. 
†All models are adjusted for age, sex, race, and methamphetamine use, except the model for methamphetamine use, which is adjusted only for age, sex, 
and race. 
‡Recent = within the 3 months prior to survey. 
§p = 0.048.  Methamphetamine Use and MRSA 
tion of something crawling on the body or under the skin, 
which can lead to skin-picking behavior, skin breakdown, 
and portals of infection. Other poor hygiene habits that can 
break the skin, such as ﬁ  ngernail biting, have been associ-
ated with MRSA SSTI (12). Methamphetamine use may 
be associated with limited access to medical care, stays 
in correctional facilities, and homelessness, all of which 
have been associated with MRSA SSTI in previous studies 
(20,22). However, our investigation did not ﬁ  nd these to be 
signiﬁ  cant risk factors for MRSA SSTI in this population.
Methamphetamine use has been associated with HIV 
(23) and sexually transmitted bacterial infections (24), 
purportedly from increased unprotected sex related to the 
sexually stimulating property of the drug. A study among 
urban HIV-positive men who have sex with men found 
that, in addition to methamphetamine use, use of other 
sexually stimulating drugs such as nitrates (“poppers”) and 
sildenaﬁ  l (e.g., Viagra) was associated with MRSA SSTI 
(12). These previous ﬁ  ndings and the results of the current 
investigation suggest that the use of methamphetamine and 
other sexually stimulating drugs may increase direct skin-
to-skin sexual contact and transmission of MRSA, which 
can be transmitted through sexual contact (25). We found 
an increased risk for MRSA SSTI in case-patients who had 
recently had sex with someone with a skin infection.
Injection of the drug may act as a method of introduc-
ing the bacteria into the skin if users fail to clean injection 
sites or share drug paraphernalia and other potentially con-
taminated items (26). Injection of methamphetamine can 
lead to transmission of bloodborne pathogens when injec-
tion equipment is shared, as demonstrated in an outbreak 
of hepatitis B among methamphetamine users in Wyoming 
(27). A recent case series of 14 patients with MRSA nec-
rotizing fasciitis found that 43% of the patients had current 
or past injection drug use (28). In contrast to early reports 
of MRSA in urban injection drug users, our investigation 
suggested that MRSA skin infections in methamphetamine 
users are not necessarily due to unclean drug injection. Few 
methamphetamine users in our population injected the drug 
or shared equipment; rather, the methamphetamine users in 
this community commonly smoked or inhaled the drug.
The absolute number of SSTIs at 1 emergency depart-
ment in this investigation increased during the 18 months 
preceding the investigation, but the percentage of MRSA 
isolates was stable over that period. This increase in SSTIs 
led to a concomitant increase in MRSA SSTIs, which were 
more common among men, and echoes repeated reports of 
MRSA SSTI outbreaks in male populations (20,29). This 
sex difference was not due to increased methamphetamine 
use in men in our population, since our population of sur-
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Table 3. Antimicrobial susceptibility patterns and toxin gene presence of selected MRSA and MSSA isolates* 
Antimicrobial agent or toxin   MRSA isolates† (N = 32), no. (%)   MSSA isolates (N = 13), no. (%) 
Antimicrobial susceptibility 
  Chloramphenicol  32 (100.0)  10 (76.9)‡ 
  Clindamycin  32 (100.0)  12 (92.3) 
    Inducible resistance (D-zone test)  0 1 (7.7) 
  Daptomycin  32 (100.0)  13 (100.0) 
  Doxycycline  32 (100.0)  13 (100.0) 
  Erythromycin  2 (6.5)  6 (46.2) 
  Gentamicin   32 (100.0)   13 (100.0) 
  Levofloxacin  27 (84.4)  12 (92.3) 
  Linezolid  32 (100.0)   13 (100.0) 
 Penicillin    0 2  (15.4) 
  Rifampin  32 (100.0)  13 (100.0) 
  Trimethoprim-sulfamethoxazole  32 (100.0)  13 (100.0) 
  Vancomycin    32 (100.0)  13 (100.0) 
Toxin gene presence 
  Panton-Valentine leukocidin  32 (100.0)  5 (38.5) 
 TSST–1  0 0
*MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; TSST, toxic shock syndrome toxin. 
†Methicillin resistance was determined by the oxacillin MIC and disk diffusion using a 30-μg cefoxitin disk (14). 
‡Three (23.1%) isolates had intermediate resistance to chloramphenicol. 
Figure 1. Number of Staphylococcus aureus skin infections at a 
southeastern United States emergency department, January 
2004–September 2005.RESEARCH
veyed methamphetamine users was evenly divided between 
the sexes. We also did not ﬁ  nd many MRSA infections in 
nonwhite patients. This ﬁ   nding contrasts with previous 
reports of higher incidence of MRSA SSTIs in African 
Americans in urban centers compared to other races (4) and 
likely reﬂ  ects the predominantly white racial distribution 
(98.9%) in these 3 rural southeastern US counties (13).
The laboratory investigation found that the most com-
mon MRSA strain causing community SSTI was PFGE 
type USA300-0114, a highly conserved strain that has been 
implicated in multiple community outbreaks (19). The sec-
ond most common MRSA strain in this community, and 
the only other strain found among methamphetamine us-
ers, was USA300-0047, which has only a 1-band difference 
from USA300-0114. MRSA SSTIs in methamphetamine 
users were not due to a novel or unusual strain of MRSA 
but rather the most common strain of MRSA in community 
settings across the United States.
Our investigation is subject to some limitations. First, 
we did not identify nor do we have data on every SSTI pa-
tient who came to the participating clinics and emergency 
departments for treatment; not every patient with SSTI pro-
vided specimens for culture or participated in our survey. 
Second, we relied on patient report of methamphetamine use 
and did not conduct drug screens for conﬁ  rmation. Third, we 
excluded patients who could only speak Spanish, which may 
have added to the low number of Hispanic study participants 
and affected the generalizability of the results. However, 
Hispanic, foreign-born, and non-English primary speakers 
each comprise only 5%–10% of the population of these 3 
counties (13). Fourth, we were unable to test for other physi-
ologic theories of why methamphetamine may be associated 
with MRSA, which include weakening the immune system 
and predisposing users to MRSA carriage by changing the 
nasal environment. Fifth, we were unable to test whether 
methamphetamine itself or drug paraphernalia were contam-
inated with MRSA. Lastly, transmission of MRSA in this 
population may have occurred in either the community or 
in the healthcare setting; for some cases, we were unable to 
determine the origin of the community strains.
Our investigation has direct implications for clinicians. 
Most clinicians in the participating emergency departments 
and urgent care clinics did not routinely drain or culture 
SSTIs. Incision and drainage is a primary therapy for SSTI, 
and empiric antimicrobial drug therapy may be given in 
addition to incision and drainage (30). Because of the 
growing and changing resistance patterns in the commu-
nity, clinicians should consider culturing SSTI (30). In this 
population, antimicrobial agents currently recommended 
for treatment of MRSA (e.g., clindamycin, doxycycline, 
and trimethoprim-sulfamethoxazole) would be appropri-
ate choices for empiric treatment of outpatient SSTI be-
cause of low prevalence of resistance (30.) Patients should 
also be educated about the risks for transmission through 
household and sexual skin-to-skin contact. Transmission of 
MRSA in this community is likely due to various factors, 
and some of these community strains may have been trans-
mitted through healthcare exposure.
Patients with MRSA SSTIs who seek treatment may 
help clinicians identify a vulnerable population of metham-
phetamine users. Prevention measures, such as improved 
hygiene and correct care for wounds, may be helpful when 
directed at methamphetamine users. However, MRSA SSTIs 
in methamphetamine users may also impact family and com-
munity members who do not use methamphetamine. The 
same strains of MRSA were circulating among both users 
and nonusers in our investigation. Public health ofﬁ  cials and 
clinicians should be aware of proper identiﬁ  cation, appro-
priate treatment, prevention of MRSA SSTIs, and the link 
between methamphetamine use and these SSTIs. 
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